5 Dementia Medications that are Approved or in Clinical Trials

2. Donanemab

Donanemab is manufactured by Eli Lilly and Company ( NYSE:LLY), which was recently in the news for significantly reducing the price of insulin, thereby providing to relief to millions of people in the U.S. According to a phase 3 study of the drug “Nearly half (47%) of the participants on donanemab (compared to 29% on placebo) had no clinical progression at 1 year (defined as no decline in CDR-SB) Phase 3 trial met primary endpoint and all secondary endpoints measuring cognitive and functional decline Donanemab treatment slowed clinical decline by 35% compared to placebo, and resulted in 40% less decline on the ability to perform activities of daily living. Over half of all participants completed their course of treatment by 12 months”. While still in trial, the drug seems to be very promising and could drastically improve the lives of those living with dementia.